Skip to main content
Figure 1 | BMC Pharmacology

Figure 1

From: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

Figure 1

Comparison of single agent rapamycin treatment to rapamycin plus IFN-g treatment in Tsc2+/- mice using a dosing schedule that includes weekly maintenance rapamycin treatment. Severity of kidney disease in Tsc2+/- mice was quantified by scoring (a) total kidney cystadenomas and (b) kidney lesion subtype for indicated treatment groups (see treatment details in methods and Table 1). Lesion subtypes include cystic, pre-papillary, papillary, and solid; for a definition of each subtype and scoring details, see Tables 2 and 3. The red error bars in (a) indicate a statistically significant difference (p < 0.05) relative to the untreated cohort. Statistical analysis was not done for the lesion subtype date. These data show a significant reduction of kidney disease in both treatment groups but no difference between single agent rapamycin and combination rapamycin plus IFN-g. Error bars shown indicate standard error.

Back to article page

BMC Pharmacology

ISSN: 1471-2210